In particular, PDE4B, which is targeted by FDA-approved medications for chronic obstructive pulmonary disease and psoriasis/psoriatic arthritis, has shown evidence of reducing alcohol consumption71,72 and is under investigation as a treatment target for AUD (NCT05414240), weight loss, and other metabolic conditions73–75. Here, PDE4B is linked to chronic obstructive pulmonary disease.